PharmaDrug, a Toronto-based specialty pharmaceutical company, partnered with a psychedelic pharmaceutical company, PharmaTher, to study the delivery of N,N-dimethyltryptamine (DMT) using PharmaTher’s novel microneedle patch (MN- patch) delivery technology.
Under the terms of the agreement, both companies will work on a product and clinical development plan to initiate regulatory discussions to use DMT MN-patch for various indications such as major depressive disorder. PharmaTher has already completed a non-clinical research study with the Terasaki Institute for Biomedical Innovation (TIBI) to evaluate the delivery of DMT MN-patch and the results are expected to be released in Q2 2023.
Founded in 2011, PharmaDrug is focused on developing treatments based on controlled substances and natural medicines such as psychedelics and cannabis. The company operates three subsidiaries: PharmaDrug GmbH, a legal medical cannabis distributor in Germany and the EU; Super Smart, an adult-use psychedelic retail business; and Sairiyo Therapeutics, a recently acquired biotech company focusing on natural therapeutics.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.